Search Medical Condition
Please enter condition
Please choose location from dropdown

T?bingen, Germany Clinical Trials

A listing of T?bingen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (209) clinical trials

Patients are needed to participate in a clinical research study for the treatment of Breast Cancer

IBC IBC is a rare but rapidly growing form of breast cancer. Currently, there are no known risk factors and biological features (such as in the genes) that researchers can use to help design better treatments for IBC. Study Participation: If you are diagnosed with IBC or the doctor believes ...

Phase N/A

0.0 miles

Learn More »

Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

The purpose of this study is to investigate whether the addition of oral maintenance chemotherapy with O-TIE (Etoposide, Idarubicin, Trofosfamide) for 6 months improves the event free survival (EFS) in patients with localised high-risk RMS and RMS-like Soft Tissue Sarcoma.

Phase

0.0 miles

Learn More »

Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

The present study is a multicenter, prospective phase III-study comparing dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML. The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year ...

Phase

0.0 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate the Safety Efficacy and Pharmacokinetics of ARGX-113 in Patients With ITP

This is a randomized, double-blind, placebo-controlled Phase II study in which approximately 36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition to Standard-of-Care (SoC) treatment. Patients aged 18 ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Participants will be assigned to receive study treatment until disease recurrence, unacceptable adverse events (AEs), intercurrent illness that prevents further administration of treatment, Investigator's decision to withdraw the participant, noncompliance with study treatment or procedural requirements, administrative reasons requiring cessation of treatment, or until the participant has received 17 cycles ...

Phase

0.0 miles

Learn More »

An European Union (EU) Post-Approval Registry of the TREO Stent-Graft

This is a prospective, multicenter, post-market clinical follow-up, non-randomized registry of the TREO Stent-Graft. Subjects diagnosed with infrarenal aortic aneurysms and treated with the TREO Stent-Graft or TREO aorto-uni-iliac (AUI) device can be included into the registry. Pre-procedure baseline data will be gathered as well as post-procedure assessments prior to ...

Phase N/A

0.0 miles

Learn More »

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab. A dose expansion cohort at the Recommended Phase Two Dose (RPTD) will be added. Adult patients with advanced (unresectable or metastatic) cutaneous melanoma primary ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

Phase

0.0 miles

Learn More »

Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

This study evaluates intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

Phase

0.0 miles

Learn More »